Senator Hawley criticizes FDA approval of new abortion drug

Republican Senator Josh Hawley from Missouri has sharply criticized the Food and Drug Administration for approving a new abortion drug, raising concerns about women's safety and the agency's trustworthiness. In a letter to FDA Commissioner Robert Califf, Hawley accused the agency of prioritizing politics over science. The move highlights ongoing debates over abortion access and regulatory oversight.

Supreme Court upholds FDA approval of mifepristone

30 сентября 2025 Сообщено ИИ

The U.S. Supreme Court unanimously ruled on June 13, 2024, that the FDA's approval of the abortion pill mifepristone is valid and remains in effect. The decision dismissed challenges from anti-abortion groups, affirming the agency's regulatory authority. This ruling ensures continued access to medication abortion, which accounts for more than half of U.S. abortions.

Federal judge strikes down FDA limits on abortion pill

A U.S. federal judge in Maryland ruled that the FDA's restrictions on the abortion medication mifepristone were unlawful, benefiting plaintiffs from three states. The decision blocks requirements for in-person dispensing and a reduced gestational age limit. This preserves broader access to the drug used in most medication abortions.

Federal judge blocks Idaho abortion ban in emergencies

3 октября 2025 Сообщено ИИ

A federal judge in Idaho has ruled that the state's strict abortion ban cannot be enforced in medical emergencies, providing temporary relief to healthcare providers. The decision addresses concerns that the law endangers women by creating uncertainty in critical situations. This ruling comes amid ongoing legal challenges to post-Roe v. Wade restrictions.